It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKRO’s FA Score shows that 0 FA rating(s) are green whileIOVA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKRO’s TA Score shows that 5 TA indicator(s) are bullish while IOVA’s TA Score has 5 bullish TA indicator(s).
AKRO (@Biotechnology) experienced а +4.84% price change this week, while IOVA (@Biotechnology) price change was -4.07% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.74%. For the same industry, the average monthly price growth was -7.78%, and the average quarterly price growth was +1.53%.
AKRO is expected to report earnings on Mar 13, 2025.
IOVA is expected to report earnings on Feb 26, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
AKRO | IOVA | AKRO / IOVA | |
Capitalization | 2.14B | 2.48B | 86% |
EBITDA | -232.85M | -388.32M | 60% |
Gain YTD | 33.619 | 0.123 | 27,331% |
P/E Ratio | N/A | N/A | - |
Revenue | 0 | 90.9M | - |
Total Cash | 717M | 397M | 181% |
Total Debt | 36.4M | 78.9M | 46% |
IOVA | ||
---|---|---|
OUTLOOK RATING 1..100 | 67 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AKRO | IOVA | |
---|---|---|
RSI ODDS (%) | 1 day ago83% | 2 days ago89% |
Stochastic ODDS (%) | 1 day ago84% | 2 days ago81% |
Momentum ODDS (%) | 1 day ago81% | 2 days ago89% |
MACD ODDS (%) | 1 day ago80% | 2 days ago90% |
TrendWeek ODDS (%) | 1 day ago83% | 2 days ago85% |
TrendMonth ODDS (%) | 1 day ago82% | 2 days ago84% |
Advances ODDS (%) | 3 days ago84% | 15 days ago83% |
Declines ODDS (%) | 7 days ago83% | 2 days ago86% |
BollingerBands ODDS (%) | 1 day ago90% | 2 days ago85% |
Aroon ODDS (%) | 1 day ago82% | 2 days ago87% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MIGIX | 17.77 | 0.26 | +1.48% |
Morgan Stanley Inst Global Insgt I | |||
FNEEX | 66.79 | 0.30 | +0.45% |
American Funds New Economy 529-F-2 | |||
LICPX | 15.22 | N/A | N/A |
Lord Abbett International Equity P | |||
GGOTX | 17.27 | N/A | N/A |
Goldman Sachs Mid Cap Growth Inv | |||
BGESX | 13.72 | N/A | N/A |
Baillie Gifford International Growth I |
A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.
Ticker / NAME | Correlation To AKRO | 1D Price Change % | ||
---|---|---|---|---|
AKRO | 100% | +1.84% | ||
ETNB - AKRO | 62% Loosely correlated | +5.01% | ||
BEAM - AKRO | 48% Loosely correlated | -3.72% | ||
PLRX - AKRO | 45% Loosely correlated | +0.94% | ||
DNLI - AKRO | 45% Loosely correlated | -0.82% | ||
VERV - AKRO | 44% Loosely correlated | +1.10% | ||
More |
A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then CRSP could also see price increases.
Ticker / NAME | Correlation To IOVA | 1D Price Change % | ||
---|---|---|---|---|
IOVA | 100% | -0.61% | ||
CRSP - IOVA | 47% Loosely correlated | +0.62% | ||
BEAM - IOVA | 45% Loosely correlated | -3.16% | ||
VCYT - IOVA | 43% Loosely correlated | +0.13% | ||
CYTK - IOVA | 42% Loosely correlated | -2.41% | ||
AKRO - IOVA | 42% Loosely correlated | -1.27% | ||
More |